Boston Chronic Kidney Disease Research Biopsy Center

波士顿慢性肾脏病研究活检中心

• 批准号: 10493645
• 负责人: Sylvia E Rosas
• 金额: $ 54.95万
• 依托单位: BOSTON MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10493645
• 关键词: Academic Medical Centers; Adult; Affect; American; Animal Model; Awareness; Biopsy; Biopsy Specimen; Boston; Budgets; Cardiovascular Diseases; Chronic Kidney Failure; Clinic; Clinical; Clinical Research; Collection; Communities; Consent Forms; Development; Diabetes Mellitus; Diabetic Nephropathy; Education; Employment; End stage renal failure; Endocrinologist; Endocrinology; Enrollment; Ensure; Ethics; Exclusion Criteria; Functional disorder; Geography; Glomerular Filtration Rate; Hospitals; Human; Hypertension; Individual; Infrastructure; Insulin-Dependent Diabetes Mellitus; Interdisciplinary Study; Investigation; Israel; Kidney; Kidney Diseases; Kidney Failure; Knowledge; Laboratories; Lead; Leadership; Literature; Longitudinal cohort study; Medical center; Molecular; Nephrology; Participant; Pathologic; Pathology; Patients; Phase; PhenX Toolkit; Population; Population Heterogeneity; Primary Care Physician; Primary Health Care; Proteome; Protocols documentation; Public Health; Radial; Renal function; Research; Research Personnel; Risk; Role; Safety; Science; Site; Spatial Distribution; Specialized Center; Techniques; Tissue Sample; Tissue atlas; Tissues; Vulnerable Populations; Woman; adjudication; base; clinical research site; cost; eligible participant; ethnic minority population; experience; follow-up; high risk; improved; inclusion criteria; insight; kidney biopsy; kidney cell; literacy; member; metabolome; molecular pathology; mortality; novel; novel strategies; patient engagement; patient population; precision medicine; protocol development; racial minority; recruit; retention rate; safety net; social health determinants; socioeconomic disadvantage; tertiary care; transcriptome

PROJECT SUMMARY Chronic kidney disease (CKD) affects 37 million Americans, costs tens of billions of dollars annually, and can lead to kidney failure, cardiovascular disease (CVD), and early mortality. CKD is not a single entity but rather a heterogeneous condition with a wide spectrum of underlying causes, pathologic and clinical manifestations, and varying rates of loss of kidney function. Because of the paucity of kidney biopsy samples from patients with common forms of CKD and the acknowledged limitations of animal models, our understanding of the pathology and molecular mechanisms of CKD is limited. Improved understanding of human CKD due to hypertension and diabetes will require investigation of kidney tissue from patients with CKD, using rapidly evolving techniques in molecular pathology. We are responding to RFA-DK-20-026 to continue as a multicenter CKD recruitment site for the Kidney Precision Medicine Project (KPMP) that builds upon the accomplishments of our established multidisciplinary research group in the UG3/UH3 phase. We propose to continue to participate as a successful CKD recruitment site in Boston, MA including four clinical sites: Joslin Diabetes Center, Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, and Boston Medical Center. The proposal builds upon an established infrastructure and our experience recruiting and retaining KPMP participants. In addition, our site has an outstanding safety record for participants with no major post-biopsy complications as well as exceeding the quality biospecimen metrics. For the U01 phase we propose to obtain repeat kidney biopsies in selected individuals as well as increase the focus on social determinants of health. We also will continue to biopsy individuals with longstanding Type 1 diabetes mellitus with no evidence of kidney pathology (‘resistors') to identify molecular underpinnings of protection against diabetic kidney disease. We are committed to continued collaborative protocol development, sharing best practices, and team science to achieve the KPMP’s objectives of advancing precision medicine to improve the lives of our patients with and at risk for CKD. The proposed research plan, by improving our understanding of CKD pathophysiology, has the potential to dramatically impact public health.

项目摘要 慢性肾脏疾病（CKD）影响3700万美国人，每年成本数十亿美元，可以 导致肾衰竭，心血管疾病（CVD）和早期死亡率。 CKD不是一个实体，而是 具有广泛的基本原因，病理和临床表现的异质状况，以及 肾功能丧失率有所不同。由于患者的肾脏活检样本很少 CKD的常见形式和动物模型的公认局限性，我们对病理的理解 CKD的分子机制受到限制。由于高血压和 糖尿病将需要使用快速发展的技术研究CKD患者的肾脏组织 分子病理学。我们正在响应RFA-DK-20-026，以继续作为多中心CKD招聘网站 对于基于我们已建立的成就的肾脏精密医学项目（KPMP） UG3/UH3阶段的多学科研究小组。我们建议继续以成功的方式参与 马萨诸塞州波士顿的CKD招聘地点包括四个临床站点：乔斯林糖尿病中心，贝丝 医疗中心，杨百翰和妇女医院和波士顿医疗中心。该提议建立在一个 建立的基础设施以及我们的经验招募和保留了毕马威会计师的参与者。此外，我们的网站 对于没有重大生物后并发症的参与者，有出色的安全记录，并且超过了 质量的生物测量指标。对于U01阶段，我们提议在选定中获得重复的肾脏活检 个人以及增加对健康社会决定者的关注。我们还将继续进行活检 长期患有1型糖尿病的人没有肾脏病理学的证据（“电阻”）以识别 保护糖尿病肾脏疾病的分子基础。我们致力于继续 协作协议开发，共享最佳实践和团队科学，以实现毕马威的目标 促进精确医学以改善患者患者的生活，并有CKD风险。提议 通过提高我们对CKD病理生理学的理解，研究计划有可能极大地影响 公共卫生。